Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1995 Sep;222(3):375–383. doi: 10.1097/00000658-199509000-00014

Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer.

S A Curley 1, F Izzo 1, A Gallipoli 1, M de Bellis 1, F Cremona 1, V Parisi 1
PMCID: PMC1234821  PMID: 7677466

Abstract

OBJECTIVE: The authors performed a prospective trial to screen patients with chronic hepatitis B or C virus (HBV, HCV) infections to (1) determine the incidence of asymptomatic hepatocellular cancer and (2) identify the subgroups at highest risk to develop hepatocellular cancer. METHODS: Four hundred sixteen patients with chronic hepatitis of more than 5 years' duration were evaluated (340 HCV, 69 HBV, 7 both). All underwent hepatic ultrasound and measurement of serum alpha-fetoprotein every 3 months. Liver biopsy was performed on entry into the study to determine the severity of hepatitis-related liver injury. RESULTS: Initial screening identified asymptomatic hepatocellular cancer in 33 patients (7.9%). Three additional liver cancers were detected during the 1st year of follow-up, bringing the overall incidence to 8.6%. Treatment with curative intent was possible in 22 of these patients (61.1%), whereas 14 (38.9%) had advanced disease. Thirty-five of these hepatocellular cancers occurred in a subset of 140 patients (25% incidence) with liver biopsies showing severe chronic active hepatitis, cirrhosis, or both, and one hepatocellular cancer occurred among the 276 patients (0.4%) with histologically less severe liver injury (p < 0.0001, chi square test). CONCLUSIONS: This screening study in patients with chronic HBV or HCV infection demonstrates (1) that the yield of asymptomatic hepatocellular cancer on initial screening is 7.9% and (2) that patients with severe chronic active hepatitis, cirrhosis, or both are at extremely high risk to develop hepatocellular cancer (25%). On the basis of these results and the finding of a significant number of small; treatable hepatocellular cancers (61.1%), the authors recommend hepatocellular cancer screening every 3 months for the subset of high-risk patients.

Full text

PDF
375

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aach R. D., Stevens C. E., Hollinger F. B., Mosley J. W., Peterson D. A., Taylor P. E., Johnson R. G., Barbosa L. H., Nemo G. J. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med. 1991 Nov 7;325(19):1325–1329. doi: 10.1056/NEJM199111073251901. [DOI] [PubMed] [Google Scholar]
  2. Acute and chronic hepatitis revisited. Review by an international group. Lancet. 1977 Oct 29;2(8044):914–919. [PubMed] [Google Scholar]
  3. Alter M. J., Mast E. E. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am. 1994 Sep;23(3):437–455. [PubMed] [Google Scholar]
  4. Alter M. J. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis. 1993 Jun;2(3):155–166. [PubMed] [Google Scholar]
  5. Beasley R. P., Hwang L. Y., Lin C. C., Chien C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. doi: 10.1016/s0140-6736(81)90585-7. [DOI] [PubMed] [Google Scholar]
  6. Bridbord K. Pathogenesis and prevention of hepatocellular carcinoma. Cancer Detect Prev. 1989;14(2):191–192. [PubMed] [Google Scholar]
  7. Colombo M., de Franchis R., Del Ninno E., Sangiovanni A., De Fazio C., Tommasini M., Donato M. F., Piva A., Di Carlo V., Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991 Sep 5;325(10):675–680. doi: 10.1056/NEJM199109053251002. [DOI] [PubMed] [Google Scholar]
  8. Cottone M., Turri M., Caltagirone M., Maringhini A., Sciarrino E., Virdone R., Fusco G., Orlando A., Marino L., Pagliaro L. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alfafetoprotein: a prospective study. Hepatogastroenterology. 1988 Jun;35(3):101–103. [PubMed] [Google Scholar]
  9. Di Bisceglie A. M., Rustgi V. K., Hoofnagle J. H., Dusheiko G. M., Lotze M. T. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 1988 Mar;108(3):390–401. doi: 10.7326/0003-4819-108-3-390. [DOI] [PubMed] [Google Scholar]
  10. Esteban J. I., González A., Hernández J. M., Viladomiu L., Sánchez C., López-Talavera J. C., Lucea D., Martin-Vega C., Vidal X., Esteban R. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med. 1990 Oct 18;323(16):1107–1112. doi: 10.1056/NEJM199010183231605. [DOI] [PubMed] [Google Scholar]
  11. Haratake J., Takeda S., Kasai T., Nakano S., Tokui N. Predictable factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer. 1993 Aug 15;72(4):1178–1183. doi: 10.1002/1097-0142(19930815)72:4<1178::aid-cncr2820720408>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  12. Ikeda K., Saitoh S., Koida I., Arase Y., Tsubota A., Chayama K., Kumada H., Kawanishi M. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993 Jul;18(1):47–53. [PubMed] [Google Scholar]
  13. Kiyosawa K., Tanaka E., Sodeyama T., Furuta K., Usuda S., Yousuf M., Furuta S. Transition of antibody to hepatitis C virus from chronic hepatitis to hepatocellular carcinoma. Jpn J Cancer Res. 1990 Nov;81(11):1089–1091. doi: 10.1111/j.1349-7006.1990.tb02517.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kuo G., Choo Q. L., Alter H. J., Gitnick G. L., Redeker A. G., Purcell R. H., Miyamura T., Dienstag J. L., Alter M. J., Stevens C. E. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989 Apr 21;244(4902):362–364. doi: 10.1126/science.2496467. [DOI] [PubMed] [Google Scholar]
  15. Lai E. C., Fan S. T., Lo C. M., Chu K. M., Liu C. L., Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995 Mar;221(3):291–298. doi: 10.1097/00000658-199503000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Liaw Y. F., Tai D. I., Chen T. J., Chu C. M., Huang M. J. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver. 1986 Jun;6(3):133–137. doi: 10.1111/j.1600-0676.1986.tb00279.x. [DOI] [PubMed] [Google Scholar]
  17. Liaw Y. F., Tai D. I., Chu C. M., Lin D. Y., Sheen I. S., Chen T. J., Pao C. C. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology. 1986 Feb;90(2):263–267. doi: 10.1016/0016-5085(86)90919-4. [DOI] [PubMed] [Google Scholar]
  18. Livraghi T., Bolondi L., Lazzaroni S., Marin G., Morabito A., Rapaccini G. L., Salmi A., Torzilli G. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992 Feb 15;69(4):925–929. doi: 10.1002/1097-0142(19920215)69:4<925::aid-cncr2820690415>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  19. Livraghi T., Bolondi L., Lazzaroni S., Marin G., Morabito A., Rapaccini G. L., Salmi A., Torzilli G. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992 Feb 15;69(4):925–929. doi: 10.1002/1097-0142(19920215)69:4<925::aid-cncr2820690415>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  20. Maringhini A., Cottone M., Sciarrino E., Marcenó M. P., La Seta F., Fusco G., Rinaldi F., Pagliaro L. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci. 1988 Jan;33(1):47–51. doi: 10.1007/BF01536630. [DOI] [PubMed] [Google Scholar]
  21. Nagasue N., Kohno H., Chang Y. C., Taniura H., Yamanoi A., Uchida M., Kimoto T., Takemoto Y., Nakamura T., Yukaya H. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg. 1993 Apr;217(4):375–384. doi: 10.1097/00000658-199304000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nomura F., Ohnishi K., Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989 Oct 15;64(8):1700–1707. doi: 10.1002/1097-0142(19891015)64:8<1700::aid-cncr2820640824>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  23. Ozawa K., Takayasu T., Kumada K., Yamaoka Y., Tanaka K., Kobayashi N., Inamoto T., Shimahara Y., Mori K., Honda K. Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period. Am J Surg. 1991 Jun;161(6):677–682. doi: 10.1016/0002-9610(91)91254-g. [DOI] [PubMed] [Google Scholar]
  24. Shapiro C. N., Margolis H. S. Hepatitis B epidemiology and prevention. Epidemiol Rev. 1990;12:221–227. doi: 10.1093/oxfordjournals.epirev.a036055. [DOI] [PubMed] [Google Scholar]
  25. Sugioka A., Tsuzuki T., Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery. 1993 Jun;113(6):612–618. [PubMed] [Google Scholar]
  26. Takano S., Yokosuka O., Imazeki F., Tagawa M., Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995 Mar;21(3):650–655. [PubMed] [Google Scholar]
  27. Tanaka H., Hiyama T., Tsukuma H., Fujimoto I., Yamano H., Okubo Y., Kitada A. Cumulative risk of hepatocellular carcinoma in hepatitis C virus carriers: statistical estimations from cross-sectional data. Jpn J Cancer Res. 1994 May;85(5):485–490. doi: 10.1111/j.1349-7006.1994.tb02384.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Thung S. N., Gerber M. A., Sarno E., Popper H. Distribution of five antigens in hepatocellular carcinoma. Lab Invest. 1979 Aug;41(2):101–105. [PubMed] [Google Scholar]
  29. Twu J. S., Lai M. Y., Chen D. S., Robinson W. S. Activation of protooncogene c-jun by the X protein of hepatitis B virus. Virology. 1993 Jan;192(1):346–350. doi: 10.1006/viro.1993.1041. [DOI] [PubMed] [Google Scholar]
  30. Unoura M., Kaneko S., Matsushita E., Shimoda A., Takeuchi M., Adachi H., Kawai H., Urabe T., Yanagi M., Matsui O. High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology. 1993 Aug;40(4):305–310. [PubMed] [Google Scholar]
  31. Verbaan H., Widell A., Lindgren S., Lindmark B., Nordenfelt E., Eriksson S. Hepatitis C in chronic liver disease: an epidemiological study based on 566 consecutive patients undergoing liver biopsy during a 10-year period. J Intern Med. 1992 Jul;232(1):33–42. doi: 10.1111/j.1365-2796.1992.tb00547.x. [DOI] [PubMed] [Google Scholar]
  32. Yamanaka N., Okamoto E., Toyosaka A., Mitunobu M., Fujihara S., Kato T., Fujimoto J., Oriyama T., Furukawa K., Kawamura E. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer. 1990 Mar 1;65(5):1104–1110. doi: 10.1002/1097-0142(19900301)65:5<1104::aid-cncr2820650511>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  33. Zhou X. D., Tang Z. Y., Yu Y. Q., Ma Z. C. Clinical evaluation of cryosurgery in the treatment of primary liver cancer. Report of 60 cases. Cancer. 1988 May 1;61(9):1889–1892. doi: 10.1002/1097-0142(19880501)61:9<1889::aid-cncr2820610928>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES